Pharmafile Logo

infill healthcare communications

- PMLiVE

Smarter Learning and Better Outcomes: How AI Can Provide an Advantage in Medical Education

See how AI-powered patient avatars allow physicians to test complex diagnoses and treatment plans in a simulated environment.

Impetus Digital

- PMLiVE

UCB’s Kygevvi receives positive CHMP opinion for thymidine kinase 2 deficiency

TK2d is an extremely rare disease characterised by severe and progressive muscle weakness

- PMLiVE

Sanofi announces positive results for venglustat in type 3 Gaucher disease

There are currently no approved treatments for the neurological symptoms of this disease

- PMLiVE

New Webinar: 2026 Engagement Strategies For Modern Pharma

Turn interaction into intelligence! Don’t miss this chance to lead the industry with our free pharma-exclusive webinar!

Impetus Digital

- PMLiVE

Havas Life London unveils AI awareness campaign

The campaign highlights the dangers of AI misinformation in rare disease

- PMLiVE

FDA approves first gene therapy for Wiskott-Aldrich syndrome

Symptoms of the rare disease include bleeding, eczema and frequent infections

Healthcare setting

Clinical research in 2026: The trends shaping tomorrow

Discover the key trends shaping clinical research in 2026, from patient-centric approaches to empowering site staff and fostering stronger human connections.

Cuttsy + Cuttsy

- PMLiVE

AstraZeneca announces $2bn investment in US manufacturing

The new and expanded facilities will support production of rare disease drug treatments

- PMLiVE

AstraZeneca reports positive results from rare disease trial

HES is a group of rare disorders characterised by persistently elevated levels of white blood cells

- PMLiVE

Minds + Assembly Launches Assembled Intelligence and Adds Stratevi to Expand Market Access and HEOR Solutions

New York, NY — 10.23.2025 — Minds + Assembly, a leading healthcare marketing firm, today announced the launch of Assembled Intelligence, an integrated communications and commercialization platform designed to unite...

BOLDSCIENCE

- PMLiVE

Uniphar On Track to Achieve SBTi Target of Halving Scope 1 and 2 Emissions by 2030

[Dublin, 9th October 2025] Uniphar, a global leader in pharmaceutical and medtech solutions, is making progress towards its near-term Science Based Targets initiative (SBTi) goal of halving Scope 1 and...

Uniphar

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links